A Randomized, Partially-Blinded, Active Comparator-Controlled, Dose-Ranging, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of an Adjuvanted Seasonal Recombinant Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Adjuvanted seasonal recombinant QVLP influenza vaccine Medicago (Primary) ; AS03A
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medicago
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 22 Apr 2021 Planned End Date changed from 31 Jan 2022 to 30 Apr 2022.
- 22 Apr 2021 Status changed from recruiting to active, no longer recruiting.